Bionor appoints new Chairman and three Non-Executive Directors

(Oslo, Norway, 13 May 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing the potential first therapeutic vaccine towards a functional cure for HIV announces, following today’s Annual General Meeting, the appointment of a new Chairman and three Non-Executive Directors.

•Bionor Board strengthened by Dr. Russell G. Greig, Dr. Kirsten Drejer, Dr. Bernd R. Seizinger and Dr. Thomas Hofstaetter

Russell Greig, Former President of Pharmaceuticals International, GlaxoSmithKline plc, joins as Chairman.
Kirsten Drejer, Co-Founder and Chief Executive Officer, Symphogen A/S, Bernd Seizinger, Executive Chairman of Opsona Therapeutics Ltd and Thomas Hofstaetter, former head of Business Development at Wyeth and Aventis, join as Non-Executive Directors of the board.

Welcoming the new board members to Bionor Pharma, Dr. David H. Solomon, President and Chief Executive Officer, said: “Russell, Kirsten, Bernd and Thomas bring an unrivalled breadth of healthcare experience and I am delighted to welcome them to Bionor. The experience and prestige of these new board members, alongside the other recent appointments at Bionor signal the strength of the company’s science, demonstrated by our promising HIV functional cure data announcement last week, and its intention to create a world-leading therapeutic vaccine company dedicated to improving the lives of those with the deadly HIV infection.”

Following these appointments, the Board of Bionor now consists of the following members:
•Russell Greig, Chairman
•Øystein Soug, Deputy Chairman
•Thomas Hofstaetter
•Bernd R. Seizinger
•Kirsten Drejer
•Benedicte Fossum
•Marianne Kock
•Jerome B. Zeldis

Notes for Editors

About Bionor
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company’s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV.
Bionor Pharma’s current clinical development pipeline comprises two vaccine candidates for the treatment of HIV, Vacc-4x and Vacc-C5. Vacc-4x is the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Bionor Pharma’s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through a collaboration with Celgene Corp, is investigating Vacc-4x and romidepsin in the REDUC study.

Bionor is listed on the Oslo stock exchange, under the ticker BIONOR.

More information about Bionor is available at www.bionorpharma.com.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

New board member biographies:

Dr. Russell G. Greig, Ph.D.
Dr Greig has more than 30 years’ experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations. He spent the majority of his career at GlaxoSmithKline, where he held a number of positions including GSK’s President of Pharmaceuticals International from 2003 to 2008 and Senior Vice President Worldwide Business Development. From 2008 to 2010, Dr Greig was also President of SR One, GSK’s Corporate Venture Group. He is currently Chairman of AM Pharma (The Netherlands) who recently signed an option agreement with Pfizer, and of Mint (The Netherlands) and a Board Member of Onxeo (France), as well as a Director of Tigenix (Belgium), Ablynx (Belgium) and Oryzon (Spain). He serves as a Venture Partner to Kurma Life Sciences (France). He was previously Chairman of Syntaxin (UK) (sold to Ipsen), Novagali (France) (sold to Santen), and Isconova (Sweden) (sold to Novavax). He served as acting CEO at Genocea and Isconova for an interim period. He was also a member of the Scottish Scientific Advisory Committee, reporting to the First Minister of Scotland.

Dr. Kirsten Drejer M.Sc., Ph.D.
Dr. Drejer co-founded Symphogen A/S in 2000 and serves as its Chief Executive Officer. Dr. Drejer is also a member of the Board of Directors for Symphogen. Dr. Drejer has 30 years of experience in the pharmaceutical and biotech industry. Before joining Symphogen she held several scientific and managerial positions in Novo Nordisk A/S as Corporate Facilitator, Director of Diabetes Discovery and Head of Diabetes Pharmacology. Dr. Drejer is a Board member of Vækstfonden (The Fund for Industrial Growth) and previously Danisco A/S until its acquisition by Dupont in 2011 and The Danish National Advanced Technology Foundation. Dr. Drejer holds a DISPUK diploma in Leadership & Organizational Development.

Dr. Bernd R. Seizinger, MD, Ph.D.
Dr. Bernd R. Seizinger, MD, Ph.D. has been Executive Chairman of Opsona Therapeutics Ltd. since 2011 and Chairman of the Board of Directors since 2009. From 1998 to 2009, Dr. Seizinger was President & Chief Executive Officer of GPC Biotech (Munich, Germany; Princeton, NJ, USA; and Cambridge/Waltham, MA, USA) until GPC Biotech was merged into Agennix AG in 2009 (Dr. Seizinger is currently a Member of the Board of Directors of Agennix). From 1996 to 1998, Dr. Seizinger was EVP and CSO of Genome Therapeutics Corp. in Waltham/Boston, MA, USA. From 1992 to 1996, he was VP of Oncology Drug Discovery and VP of Corporate and Academic Alliances at Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ, USA. Dr. Seizinger was on faculty at Massachusetts General Hospital and Harvard Medical School in Boston, MA, USA (1984-1992). Dr. Seizinger also held a visiting faculty position at the Department of Molecular Biology at Princeton University. He was awarded his M.D. from the Ludwig-Maximilians-University and his Ph.D. (summa cum laude) from the Max Planck Institute of Psychiatry both of which are located in Munich, Germany. He is the recipient of a number of scientific awards and has authored over one hundred publications.

Dr. Thomas Hofstaetter Ph.D.
Dr. Thomas Hofstaetter has more than 30 years’ experience in the pharmaceutical industry from a broad range of senior executive positions spanning R&D, strategy and corporate development. Dr. Hofstaetter has served as a director of Onxeo since May 2012 and Geron Corporation since March 2010. From January 2010 to December 2011, he was President, Chief Executive Officer and a director of VaxInnate Corporation. From September 2004 to October 2009, Dr. Hofstaetter was Senior Vice President, Corporate Development and Head of Global Business Development and a member of the Wyeth Management Committee at Wyeth, Inc. From December 1999 to August 2004, Dr. Hofstaetter was Senior Vice President of Corporate Development of Aventis. From 1991 to 1999, Dr. Hofstaetter served in various executive managerial positions around the world, including the United States, Japan (as General Manager, Pharma), France and his native Germany, with Hoechst Pharma. In 1978, Dr. Hofstaetter joined Behringwerke AG in Germany as a research scientist and rose to become head of Research in 1988 and head of the Immunology/Oncology business unit in 1989. Dr. Hofstaetter holds a Master of Science degree in Biochemistry and a Ph.D. in Molecular Biology, magna cum laude, from the University of Tuebingen in Germany.

For more information please contact:
Bionor Pharma ASA
President and Chief Executive Officer David Solomon:
Tel + 45 22 20 63 00

Consilium Strategic Communications
Mary-Jane Elliott / Ivar Milligan / Jessica Hodgson / Hendrik Thys
bionor@consilium-comms.com
+44 (0)20 3709 5700